dc.contributor.author |
Rentzos, M |
en |
dc.contributor.author |
Nikolaou, C |
en |
dc.contributor.author |
Andreadou, E |
en |
dc.contributor.author |
Paraskevas, GP |
en |
dc.contributor.author |
Rombos, A |
en |
dc.contributor.author |
Zoga, M |
en |
dc.contributor.author |
Tsoutsou, A |
en |
dc.contributor.author |
Boufidou, F |
en |
dc.contributor.author |
Kapaki, E |
en |
dc.contributor.author |
Vassilopoulos, D |
en |
dc.date.accessioned |
2014-03-01T01:58:51Z |
|
dc.date.available |
2014-03-01T01:58:51Z |
|
dc.date.issued |
2009 |
en |
dc.identifier.issn |
0001-6314 |
en |
dc.identifier.uri |
https://dspace.lib.ntua.gr/xmlui/handle/123456789/28757 |
|
dc.subject |
IL-12 |
en |
dc.subject |
IL-10 |
en |
dc.subject |
Serum |
en |
dc.subject |
ELISA |
en |
dc.subject |
Parkinson's disease |
en |
dc.subject |
immunological disturbances |
en |
dc.subject |
l-dopa treatment |
en |
dc.subject.classification |
Clinical Neurology |
en |
dc.subject.other |
TUMOR-NECROSIS-FACTOR |
en |
dc.subject.other |
FACTOR-ALPHA |
en |
dc.subject.other |
ALZHEIMERS-DISEASE |
en |
dc.subject.other |
CYTOKINE PRODUCTION |
en |
dc.subject.other |
MULTIPLE-SCLEROSIS |
en |
dc.subject.other |
MICROGLIAL CELLS |
en |
dc.subject.other |
IL-10 |
en |
dc.subject.other |
BRAIN |
en |
dc.subject.other |
LIPOPOLYSACCHARIDE |
en |
dc.subject.other |
ISCHEMIA |
en |
dc.title |
Circulating interleukin-10 and interleukin-12 in Parkinson's disease |
en |
heal.type |
journalArticle |
en |
heal.language |
English |
en |
heal.publicationDate |
2009 |
en |
heal.abstract |
Interleukin (IL)-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines. IL-10 is a pleiotropic cytokine produced by both lymphocytes and mononuclear phagocytes including microglia. Recent studies demonstrated the neuroprotective effect of IL-10. There is little information about the involvement of IL-12 or IL-10 in the pathophysiology of Parkinson's disease (PD). The objective of our study was to assess the role of IL-12 as a potential marker of immune reactions in patients with PD and to investigate whether IL-10, an immunosuppressive cytokine, may have a neuroprotective effect in the pathogenesis of PD. We measured using immunoassay serum IL-12 and IL-10 levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects (controls) age and sex matched. IL-12 and IL-10 levels were tested for correlation with sex, age, disease duration, Hoehn and Yahr stage and the UPDRS III score. The PD group presented with significantly increased IL-10 levels when compared with the control group (P = 0.02). The increase observed was not affected by the treatment status. A strong and significant correlation between IL-10 and IL-12 levels was observed in patients with PD (R-S = 0.7, P < 0.000001). Our findings suggest that IL-10 may be involved in the pathogenetic mechanisms of PD. The elevation of IL-10 and the significant correlation between IL-10 and IL-12, a proinflammatory cytokine, may suggest that immunological disturbances and neuroprotective mechanisms are involved in patients with PD. |
en |
heal.publisher |
WILEY-BLACKWELL PUBLISHING, INC |
en |
heal.journalName |
ACTA NEUROLOGICA SCANDINAVICA |
en |
dc.identifier.isi |
ISI:000265069900007 |
en |
dc.identifier.volume |
119 |
en |
dc.identifier.issue |
5 |
en |
dc.identifier.spage |
332 |
en |
dc.identifier.epage |
337 |
en |